Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIG31: NP-016 Vaccinia Immune Globulin for Ocular Complications of Vaccinia Vaccination
NCT00081835Phase 2Completed
- Sponsor
- National Eye Institute
- Start
- Apr 2004
- Modality
- IgG Antibodies, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in Vaccinia Keratitis comparing VIGIV + Standard of Care with Placebo + Standard of Care (2 arms). Primary endpoint: Proportion of patients with corneal scarring at 1 year. Started Apr 2004; status: completed.
02
Drugs
Human vaccinia virus immune globulin
03
Conditions
Vaccinia Keratitis
Beyond the preview
Go deeper on NCT00081835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081835.